# US 6,727,070 B2 · Protein/solubility folding assessed by structural complementation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,070 B2
- Document ID: US6727070B2
- Status: Granted
- Kind: B2
- Application number: 09/775,051
- Filed: 2001-01-31
- Published: 2004-01-01
- Granted: 2004-04-27
- Earliest claimed: 2000-02-14
- Assignees: Board of Regents, The University of Texas System; The Trustees of Columbia University in the City of New York
- Inventors: Philip Jordan Thomas; John F. Hunt; William Christian Wigley; Rhesa D. Stidham
- Web page: https://patentgrep.com/patent/US6727070B2

## CPC

- G01N 33/502: {for testing non-proliferative effects}
- C07K 1/113: without change of the primary structure
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Many proteins, when produced recombinantly, suffer from improper processing, folding and lack normal solubility. Modified proteins, including those indicative of disease states, also can have such defects. The present invention is directed to methods of identifying proper and improper protein folding, aberrant processing and/or insolubility. The method relies on the use of two components: a specialized fusion protein and structural complementation. The fusion protein contains sequences from the protein of interest and one portion of a marker protein that, by itself, is not active. A host cell then provides the remainder of the marker protein that serves to “complement” the function of the fused marker protein such that their association restores activity, permitting detection.

## Claims

### Claim 1

A method for determining proper folding and/or solubility of a protein of interest comprising:
a) providing an expression construct comprising (i) a gene encoding a first polypeptide comprising said protein of interest fused to a first segment of a marker protein, and (ii) a promoter active in a selected host cell and operably linked to said gene;
b) expressing said first polypeptide in said host cell that also expresses a second segment of said marker protein, wherein said second marker segment combines with said first marker segment to form a functional marker protein when said first polypeptide is properly folded; and
c) measuring marker protein function,
wherein a greater degree of marker protein function, as compared to marker protein function observed with appropiate negative controls, indicates proper folding and/or solubility of said protein of interest.

### Claim 2 (depends on 1)

The method of claim 1, wherein said first polypeptide comprises said first marker segment fused C-terminal to said protein of interest.

### Claim 3 (depends on 1)

The method of claim 1, wherein said first polypeptide comprises said first marker segment fused N-terminal to said protein of interest.

### Claim 4 (depends on 1)

The method of claim 1, wherein said marker protein is selected from the group consisting of a protein that binds said protein of interest, an enzyme, a protein inhibitor, a fluorophore and a chromophore.

### Claim 5 (depends on 4)

The method of claim 4, wherein said marker protein is a protein that binds said protein of interest.

### Claim 6 (depends on 5)

The method of claim 5, wherein said target binding protein is ubiquitin.

### Claim 7 (depends on 4)

The method of claim 4, wherein said marker protein is a chromophore.

### Claim 8 (depends on 7)

The method of claim 7, wherein said chromophore is green fluorescent protein, blue fluorescent protein, yellow fluorescent protein, luciferase or aquorin.

### Claim 9 (depends on 4)

The method of claim 4, wherein said marker protein is an enzyme.

### Claim 10 (depends on 9)

The method of claim 9, wherein said enzyme is β-galactosidase, cytochrome c, chymotrypsin inhibitor, Rnase, phosphoglycerate kinase, invertase, staphylococcal nuclease, thioredoxin C, lactose permease, amino acyl tRNA synthase, and dihydrofolate reductase.

### Claim 11 (depends on 10)

The method of claim 10, wherein said enzyme is β-galactosidase.

### Claim 12 (depends on 11)

The method of claim 11, wherein said first marker segment is the α-peptide of β-galactosidase, and said second segment is the ω-peptide of β-galactosidase.

### Claim 13 (depends on 1)

The method of claim 1, wherein said protein of interest is Alzheimer's amyloid peptide (Aβ), SOD1, presenillin 1 and 2, α-synuclein, amyloid A, amyloid P, CFTR, transthyretin, amylin, lysozyme, gelsolin, p53, rhodopsin, insulin, insulin receptor, fibrillin, α-ketoacid dehydrogenase, collagen, keratin, PRNP, immunoglobin light chain, atrial, natriuretic, peptide, seminal vesicle exocrine protein, β2-microglobulin, PrP, precalcitonin, ataxin 1, ataxin 2, ataxin 3, ataxin 6, ataxin 7, huntingtin, androgen receptor, CREB-binding protein, dentaorubral pallidoluysian strophy-associated protein, maltrose-binding protein, ABC transporter, glutathione S transferase, and thioredoxin.

### Claim 14 (depends on 1)

The method of claim 1, wherein a gene according said second polypeptide is carried on a chromosome of said host cell.

### Claim 15 (depends on 1)

The method of claim 1, wherein a gene encoding said second polypeptide is carried episomally in said host cell.

### Claim 16 (depends on 1)

The method of claim 1, wherein said host cell is selected from the group consisting of a bacterial cell, an insect cell, a yeast cell, a nematode cell, and a mammalian cell.

### Claim 17 (depends on 16)

The method of claim 16, wherein said host cell is a bacterial cell.

### Claim 18 (depends on 17)

The method of claim 17, wherein said bacterial cell is E. coli.

### Claim 19 (depends on 18)

The method of claim 18, wherein said promoter is the Taq promoter, T7 promoter, or the Plac promoter.

### Claim 20 (depends on 16)

The method of claim 16, wherein said host cell is a nematode cell.

### Claim 21 (depends on 20)

The method of claim 20, wherein said nematode cell is a Caenorhabditis elegans cell.

### Claim 22 (depends on 16)

The method of claim 16, wherein said host cell is an insect cell.

### Claim 23 (depends on 22)

The method of claim 22, wherein said host cell is a Spodopiera frugiperda cell.

### Claim 24 (depends on 16)

The method of claim 16, wherein said host cell is a yeast cell.

### Claim 25 (depends on 14)

The method of claim 14, wherein said promoter is CupADH or Gal.

### Claim 26 (depends on 16)

The method of claim 16, wherein said host cell is a mammalian cell.

### Claim 27 (depends on 26)

The method of claim 26, wherein said promoter is PepCk or tk.

### Claim 28 (depends on 1)

The method of claim 1, wherein said negative control utilize a host cell lacking the second polypeptide.

### Claim 29 (depends on 1)

The method of claim 1, wherein said negative control ulitizes a fusion protein that is improperly folded and/or insoluble.
